Article
Oncology
Daniela Cocco, Ayat ElSherif, Matthew D. Wright, Marcus S. Dempster, Megan L. Kruse, Hong Li, Stephanie A. Valente
Summary: Invasive lobular carcinoma is a unique subset of cancer with diagnostic staging challenges. The study results support the use of MRI for accurate tumor staging and improved detection of multicentricity and bilaterality. However, clinicians should be aware of the higher likelihood of occult lymph node involvement with ILC and subsequent early metastasis.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Rusen Cosar, Necdet Sut, Sernaz Topaloglu, Ebru Tastekin, Dilek Nurlu, Talar Ozler, Eylul Senodeyici, Melisa Dedeli, Mert Chousein, Irfan Cicin
Summary: This study compared the clinical features and prognosis of invasive lobular carcinoma patients and found that the invasive lobular special type had the worst prognosis, suggesting a need for reclassification and reconsideration of treatment methods.
Article
Oncology
Agostina Nardone, Xintao Qiu, Sandor Spisak, Zsuzsanna Nagy, Ariel Feiglin, Avery Feit, Gabriela Cohen Feit, Yingtian Xie, Alba Font-Tello, Cristina Guarducci, Francisco Hermida-Prado, Sudeepa Syamala, Klothilda Lim, Miguel Munoz Gomez, Matthew Pun, MacIntosh Cornwell, Weihan Liu, Aysegul Ors, Hisham Mohammed, Paloma Cejas, Jane B. Brock, Matthew L. Freedman, Eric P. Winer, Xiaoyong Fu, Rachel Schiff, Henry W. Long, Otto Metzger Filho, Rinath Jeselsohn
Summary: Most invasive lobular breast cancers (ILC) are of the luminal A subtype and are strongly hormone receptor-positive. However, ILC is relatively resistant to tamoxifen and associated with inferior long-term outcomes compared with invasive ductal cancers (IDC). In this study, the researchers found that ILC had a unique chromatin state and FOXA1-ER axis that promoted tumor progression, offering a novel mechanism of tamoxifen resistance. These results highlight the importance of conducting clinical trials dedicated to patients with ILC to optimize treatments in this breast cancer subtype.
Article
Oncology
Fangyuan Chen, Kai Ding, Nolan Priedigkeit, Ashuvinee Elangovan, Kevin M. Levine, Neil Carleton, Laura Savariau, Jennifer M. Atkinson, Steffi Oesterreich, Adrian V. Lee
Summary: This study revealed transcriptional heterogeneity in breast cancer cell lines and the significant role of E-cadherin depletion in contributing to the molecular features of invasive lobular breast carcinoma.
Article
Oncology
Mary Kathryn Abel, Heather Greenwood, Tatiana Kelil, Ruby Guo, Case Brabham, Nola Hylton, Jasmine Wong, Michael Alvarado, Cheryl Ewing, Laura J. Esserman, Judy C. Boughey, Rita A. Mukhtar
Summary: Breast MRI after neoadjuvant therapy in patients with ILC showed low accuracy in predicting nodal status, but may help identify patients with a high burden of nodal disease (>= 4 positive nodes), potentially impacting pre-operative systemic therapy decisions. Further studies are needed to evaluate other imaging modalities for nodal disease assessment following neoadjuvant therapy in ILC patients.
Review
Oncology
Jason A. Mouabbi, Amy Hassan, Bora Lim, Gabriel N. Hortobagyi, Debasish Tripathy, Rachel M. Layman
Summary: Invasive lobular carcinoma (ILC) is the second most common subtype of breast cancer, with conflicting outcomes compared to invasive ductal carcinoma (IDC). Recent studies have shown that ILC and IDC are distinct entities.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Medicine, General & Internal
Andrew A. Davis, Lorenzo Gerratana, Katherine Clifton, Arielle J. Medford, Marko Velimirovic, Whitney L. Hensing, Leslie Bucheit, Ami N. Shah, Paolo D'Amico, Carolina Reduzzi, Qiang Zhang, Charles S. Dai, Elyssa N. Denault, Nusayba A. Bagegni, Mateusz Opyrchal, Foluso O. Ademuyiwa, Ron Bose, William J. Gradishar, Amir Behdad, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli
Summary: This study analyzed genomic differences in circulating tumor DNA (ctDNA) among patients with invasive lobular carcinoma (ILC), invasive ductal carcinoma (IDC), and mixed histology. The results showed that ILC was associated with specific HR+ HER2 negative and HER2 low characteristics. Higher levels of single nucleotide variations (SNVs) were observed in ILC patients compared to IDC or mixed histology patients. Mutations in CDFII, ERBB2, and PTEN genes were significantly associated with HR+ HER2 negative ILC. Additionally, mutations in the PI3K pathway genes were more common in ILC patients. These findings have implications for histologic classification and precision medicine treatment.
Review
Oncology
Natalie Wilson, Alastair Ironside, Anna Diana, Olga Oikonomidou
Summary: Invasive lobular carcinoma accounts for a small percentage of breast cancers but has distinctive biological and molecular features that make diagnosis and treatment challenging. This type of cancer is less responsive to chemotherapy and often requires endocrine therapy. Understanding the unique biology of lobular breast carcinoma is crucial for guiding future treatment strategies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Raquel Nunes, Tal Sella, Kai Treuner, Jennifer M. Atkinson, Jenna Wong, Yi Zhang, Pedro Exman, David Dabbs, Andrea L. Richardson, Catherine A. Schnabel, Dennis C. Sgroi, Steffi Oesterreich, Ashley Cimino-Mathews, Otto Metzger
Summary: The study evaluated the prognostic utility of the Breast Cancer Index (BCI) for assessing the risk of distant recurrence (DR) in hormone receptor-positive invasive lobular carcinoma (ILC) patients. BCI was found to be a significant independent prognostic factor for overall 10-year, early, and late DR, adding value beyond clinicopathologic characteristics.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
K. Van Baelen, T. Geukens, M. Maetens, V Tjan-Heijnen, C. J. Lord, S. Linn, F-C Bidard, F. Richard, W. W. Yang, R. E. Steele, S. J. Pettitt, C. Van Ongeval, M. De Schepper, E. Isnaldi, I Nevelsteen, A. Smeets, K. Punie, L. Voorwerk, H. Wildiers, G. Floris, A. Vincent-Salomon, P. W. B. Derksen, P. Neven, E. Senkus, E. Sawyer, M. Kok, C. Desmedt
Summary: ILC is a unique type of breast cancer with distinct pathological and biological features, leading to differences in diagnosis, treatment response, resistance, and targets compared to NST.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
John Alexander, Odette Mariani, Celine Meaudre, Laetitia Fuhrmann, Hui Xiao, Kalnisha Naidoo, Andrea Gillespie, Ioannis Roxanis, Anne Vincent-Salomon, Syed Haider, Rachael Natrajan
Summary: This study found that invasive lobular breast cancers with heterogeneous E-cadherin expression are composed of different components with a common ancestor. CDH1 gene mutations and loss of E-cadherin protein expression are characteristic of these tumors. Regardless of E-cadherin protein expression, these tumors should be considered part of the spectrum of invasive lobular breast cancers.
Article
Oncology
Siddhartha Yadav, Chunling Hu, Katherine L. Nathanson, Jeffrey N. Weitzel, David E. Goldgar, Peter Kraft, Rohan D. Gnanaolivu, Jie Na, Hongyan Huang, Nicholas J. Boddicker, Nicole Larson, Chi Gao, Song Yao, Clarice Weinberg, Celine M. Vachon, Amy Trentham-Dietz, Jack A. Taylor, Dale R. Sandler, Alpa Patel, Julie R. Palmer, Janet E. Olson, Susan Neuhausen, Elena Martinez, Sara Lindstrom, James V. Lacey, Allison W. Kurian, Esther M. John, Christopher Haiman, Leslie Bernstein, Paul W. Auer, Hoda Anton-Culver, Christine B. Ambrosone, Rachid Karam, Elizabeth Chao, Amal Yussuf, Tina Pesaran, Jill S. Dolinsky, Steven N. Hart, Holly LaDuca, Eric C. Polley, Susan M. Domchek, Fergus J. Couch
Summary: The study found that ATM, BRCA2, CDH1, CHEK2, and PALB2 pathogenic variants are associated with an increased risk of ILC, while BRCA1 pathogenic variants are not. CDH1 pathogenic variants are significantly enriched in ILC, while BRCA1 pathogenic variants are substantially reduced.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Pamela Trillo, Jose Sandoval, Dario Trapani, Eleonora Nicolo, Paola Zagami, Federica Giugliano, Paolo Tarantino, Grazia Vivanet, Liliana Ascione, Alex Friedlaender, Angela Esposito, Carmen Criscitiello, Giuseppe Curigliano
Summary: The study retrospectively analyzed data of patients with recurrent invasive lobular carcinoma (ILC) and found discordance in the expression of ER, PgR, and HER2 between primary tumors and metastases. These findings suggest that phenotypic switch during metastasis may have implications for treatment decisions and prognosis in patients with ILC.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Delal Akdeniz, Iris Kramer, Carolien H. M. van Deurzen, Bernadette A. M. Heemskerk-Gerritsen, Michael Schaapveld, Pieter J. Westenend, Adri C. Voogd, Agnes Jager, Ewout W. Steyerberg, Stefan Sleijfer, Marjanka K. Schmidt, Maartje J. Hooning
Summary: Lobular and lobular mixed primary breast cancer histology are associated with modestly increased risk of contralateral breast cancer (CBC), and personalized risk assessment needs to consider the histology of the primary cancer as well as the impact of systemic therapy.
Article
Oncology
Medha Suman, Pierre-Antoine Dugue, Ee Ming Wong, JiHoon Eric Joo, John L. Hopper, Tu Nguyen-Dumont, Graham G. Giles, Roger L. Milne, Catriona McLean, Melissa C. Southey
Summary: This study investigated the genome-wide variability of DNA methylation levels across invasive lobular breast cancer (ILBC) tumors and found that methylation at several genes may serve as a potential biomarker for survival in ILBC patients.
CLINICAL EPIGENETICS
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
S. Rivetti, B. Canossi, R. Battista, N. Lanconelli, E. Vetruccio, C. Danielli, G. Borasi, P. Torricelli
Article
Computer Science, Software Engineering
C. Casarino, G. Russo, G. C. Candiano, G. La Rocca, R. Barbera, G. Borasi, S. Guatelli, C. Messa, G. Passaro, M. C. Gilardi
CONCURRENCY AND COMPUTATION-PRACTICE & EXPERIENCE
(2015)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Giovanni Borasi, Federica Fioroni, Alberto Del Guerra, Giovanni Lucignani
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2010)
Article
Environmental Sciences
Elisa Grassi, Roberto Sghedoni, Vando Piccagli, Federica Fioroni, Giovanni Borasi, Mauro Iori
Editorial Material
Oncology
Giovanni Borasi, Andreas Melzer, Giorgio Russo, Alan Nahum, Qinghui Zhang, Filippo Alongi, Fabrizio Vicari, Maria Carla Gilardi
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2014)
Article
Radiology, Nuclear Medicine & Medical Imaging
Giorgio Russo, Carlo Casarino, Gaetano Arnetta, Giuliana Candiano, Alessandro Stefano, Filippo Alongi, Giovanni Borasi, Cristina Messa, Maria C. Gilardi
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
(2012)
Article
Radiology, Nuclear Medicine & Medical Imaging
Marco Bertolini, Andrea Nitrosi, Giovanni Borasi, Andrea Botti, Davide Tassoni, Roberto Sghedoni, Giulio Zuccoli
JOURNAL OF DIGITAL IMAGING
(2011)
Article
Radiology, Nuclear Medicine & Medical Imaging
Elisa Grassi, Roberto Sghedoni, Mattia Asti, Federica Fioroni, Diana Salvo, Giovanni Borasi
NUCLEAR MEDICINE COMMUNICATIONS
(2009)
Meeting Abstract
Oncology
G. Russo, C. Casarino, G. C. Candiano, G. Arnetta, P. Spiccia, G. Borasi, C. Messa, M. C. Gilardi
RADIOTHERAPY AND ONCOLOGY
(2011)
Review
Oncology
Filippo Alongi, Giorgio Russo, Antonio Spinelli, Giovanni Borasi, Marta Scorsetti, Maria Carla Gilardi, Cristina Messa
Review
Radiology, Nuclear Medicine & Medical Imaging
Giovanni Borasi, Giorgio Russo, Filippo Alongi, Alan Nahum, Giuliana Carmela Candiano, Alessandro Stefano, Maria Carla Gilardi, Cristina Messa
JOURNAL OF THERAPEUTIC ULTRASOUND
(2013)
Proceedings Paper
Physics, Applied
Giuliana Candiano, Giorgio Russo, Alessandro Stefano, Lorenza Marino, Francesca Ganguzza, Arturo Vaccari, Vincenzo Tripoli, Anna Galluzzo, Sabina Pulizzi, Domenico Messana, Giovanni Borasi, Cristina Messa, Maria Carla Gilardi
12TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND
(2012)
Meeting Abstract
Oncology
J. M. Udias, P. Ibanez, M. Vidal, R. Garcia-Marcos, G. Russo, C. Casarino, G. C. Candiano, G. Borasi, C. Messa, M. C. Gilardi
RADIOTHERAPY AND ONCOLOGY
(2014)
Meeting Abstract
Oncology
G. Russo, I. Fazio, C. Casarino, S. Guatelli, G. Candiano, G. La Rocca, R. Barbera, G. Borasi, C. Messa, M. C. Gilardi
RADIOTHERAPY AND ONCOLOGY
(2014)
Article
Pharmacology & Pharmacy
Mauro Iori, Marta Paiusco, Elisabetta Cagni, Silvana Riccardi, Daniele Lambertini, Nicola Bizzocchi, Gianni Borasi, Cinzia Iotti, Nunziata D'Abbiero, Alan Effraim Nahum
CURRENT RADIOPHARMACEUTICALS
(2009)